Athersys (NASDAQ:ATHX) Now Covered by StockNews.com

Research analysts at StockNews.com began coverage on shares of Athersys (NASDAQ:ATHX) in a research note issued on Friday. The brokerage set a “hold” rating on the biopharmaceutical company’s stock.

Athersys Price Performance

The stock has a market cap of $833,000.00, a price-to-earnings ratio of -0.01 and a beta of -0.90. Athersys has a 1-year low of $0.01 and a 1-year high of $1.99.

About Athersys

Athersys, Inc, a biotechnology company, focuses on the research and development activities in the field of regenerative medicine. Its clinical development programs are focused on treating neurological conditions, cardiovascular diseases, inflammatory and immune disorders, and pulmonary and other conditions.